Multiple Sclerosis

Template Improves Quality of Report on MRI for Multiple Sclerosis

Template Improves Quality of Report on MRI for Multiple Sclerosis

By

More structured MRI reports may aid in the diagnosis of multiple sclerosis.

Potential Prognostic Biomarker for Clinically Isolated Syndrome

Potential Prognostic Biomarker for Clinically Isolated Syndrome

By

It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.

Low Neonatal Vitamin D May Increase Risk of MS

Low Neonatal Vitamin D May Increase Risk of MS

By

Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.

Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression

Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression

By

Previous MRI studies focused on gray matter changes only.

Alemtuzumab May Reduce Disability in Early MS

Alemtuzumab May Reduce Disability in Early MS

By

The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.

Does Exercise Influence Risk of Multiple Sclerosis?

Does Exercise Influence Risk of Multiple Sclerosis?

By

Researchers still recommend that patients with MS engage in physical activity for cardiovascular benefits.

Experimental Multiple Sclerosis Drug May Prevent Disease in Mice

Experimental Multiple Sclerosis Drug May Prevent Disease in Mice

Researchers believe that the drug may help prevent MS, since there was a 96% reduction in harmful clusters of B cells.

Psychiatric Disorders Common in Pediatric MS, Demyelinating Diseases

Psychiatric Disorders Common in Pediatric MS, Demyelinating Diseases

By

Notably, patients who had documented psychotic and psychiatric disorders were more likely to be diagnosed with a demyelinating disease.

Dimethyl-Fumarate May Maintain NEDA After Natalizumab Discontinuation

Dimethyl-Fumarate May Maintain NEDA After Natalizumab Discontinuation

By

Over 90% of participants achieved NEDA-3 after being transitioned to dimethyl-fumarate from natalizumab.

Smoking May Accelerate White Matter Damage in Progressive MS

Smoking May Accelerate White Matter Damage in Progressive MS

By

The relationship between microstructural damage in NAWM and clinical measures was less clear, suggesting another mechanism.

Enriching Experiences May Protect Against Cognitive Decline in MS

Enriching Experiences May Protect Against Cognitive Decline in MS

By

Researchers examined whether the cognitive reserve hypothesis could predict cognitive decline, gray matter volume changes, and white matter volume changes in MS patients.

High-Fat Diets May Increase Relapse Risk in Pediatric MS

High-Fat Diets May Increase Relapse Risk in Pediatric MS

By

High-fat diets may increase the risk of relapse in children with MS, while high-vegetable diets may be protective.

Genetic Risk Score Identifies Pediatric Patients With Greater MS Relapse Risk

Genetic Risk Score Identifies Pediatric Patients With Greater MS Relapse Risk

By

Six polymorphisms were found to be strongly associated with vitamin D levels in the patient population.

Axon Diameter May Help Detect, Track Multiple Sclerosis

Axon Diameter May Help Detect, Track Multiple Sclerosis

By

Axon diameter dynamics may serve as a novel biomarker for MS disease course.

Early Tx Exposure May Prevent Progression in Pediatric Clinically Isolated Syndrome

Early Tx Exposure May Prevent Progression in Pediatric Clinically Isolated Syndrome

By

Patients at the greatest risk of disability progression were older than 12 years, and had minimal exposure to DMTs.

BMI, Lipid Levels Influence Multiple Sclerosis Disease Course

BMI, Lipid Levels Influence Multiple Sclerosis Disease Course

By

Higher BMI and lipid levels were associated with greater risk of relapse and disability progression.

Differentiating Multiple Sclerosis Mimics on MRI

Differentiating Multiple Sclerosis Mimics on MRI

By

A proper MS diagnosis can only be made after obtaining imaging from the entire brain and understanding the clinical context.

Strategies to Curb Treatment Cost in Multiple Sclerosis

Strategies to Curb Treatment Cost in Multiple Sclerosis

By

Several strategies for clinical practice and research may reduce the cost of MS treatment while maintaining efficacy.

Early Treatment and the Transition From Clinically Isolated Syndrome to MS

Early Treatment and the Transition From Clinically Isolated Syndrome to MS

By

The findings from the extension study support prior research that showed the benefits of early treatment.

Routine MRI, Clinical Assessments Fail to Predict Prognosis in MS

Routine MRI, Clinical Assessments Fail to Predict Prognosis in MS

Routine evaluation with MRI appeared to have no clinical benefit over time.

Gut Bacteria and Its Emerging Role in Multiple Sclerosis

Gut Bacteria and Its Emerging Role in Multiple Sclerosis

By

It has been proposed that the gut microbiome may be an important environmental risk factor in MS.

Successive Pregnancies Not Associated With MS Relapse Rate

Successive Pregnancies Not Associated With MS Relapse Rate

By

Among study participants, relapse rate actually decreased from the first to second pregnancy.

Gut Bacteria Profile Differs in Patients with Multiple Sclerosis

Gut Bacteria Profile Differs in Patients with Multiple Sclerosis

By

Differences in gut bacteria were apparent between patients with active RRMS and those in remission.

Pros and Cons: Vitamin D Supplementation in Multiple Sclerosis

Pros and Cons: Vitamin D Supplementation in Multiple Sclerosis

By

While supplementation has produced a positive response in disease activity, adverse events based on dosing are concerning.

Siponimod Effective in Reducing Disease Activity in Relapsing MS

Siponimod Effective in Reducing Disease Activity in Relapsing MS

By

The 2 mg dose appears to be most efficacious.

Health Insurance Status Affects Medication Use in MS

Health Insurance Status Affects Medication Use in MS

By

Nearly 25% of respondents taking DMDs use free or discounted drug programs.

BMI and Multiple Sclerosis: More Evidence of Causation

BMI and Multiple Sclerosis: More Evidence of Causation

By

A transition from overweight to obese correlated with a 41% increased risk of MS.

Ocrelizumab Granted Priority Review for Treatment of Multiple Sclerosis

Ocrelizumab Granted Priority Review for Treatment of Multiple Sclerosis

By

If approved, the monoclonal antibody will be the first treatment indicated for both RMS and PPMS.

Managing Bladder Dysfunction in Multiple Sclerosis

Managing Bladder Dysfunction in Multiple Sclerosis

By

One of the biggest hurdles is getting the patient to be honest and open with you about bladder problems.

Cerebral Microbleeds May Be Linked to Disability in Multiple Sclerosis

Cerebral Microbleeds May Be Linked to Disability in Multiple Sclerosis

By

A greater volume of microbleeds was associated with worse auditory and verbal learning and memory.

Sign Up for Free e-newsletters